Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gaston Habets

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Nature Biotechnology|November 10, 2011
Interrogating the kinomeChao Zhang, Gaston Habets, Gideon Bollag
Pain|May 21, 2015
Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancerMichelle L Thompson, Juan M Jimenez-Andrade, Stephane Chartier, et al.
Cancer Cell|December 21, 2004
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivityClodagh C O'Shea, Leisa Johnson, Bridget Bagus, et al.
Clinical and Experimental Medicine|December 8, 2018
PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumorsYemarshet K Gebreyohannes, Elizabeth A Burton, Agnieszka Wozniak, et al.
Nature Communications|August 23, 2019
Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease modelElizabeth Spangenberg, Paul L Severson, Lindsay A Hohsfield, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2013
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitorChao Zhang, Prabha N Ibrahim, Jiazhong Zhang, et al.
Cancer Discovery|April 8, 2015
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397Catherine C Smith, Chao Zhang, Kimberly C Lin, et al.
JCI Insight|July 27, 2018
The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanomaOrsi Giricz, Yongkai Mo, Kimberly B Dahlman, et al.
Nature|October 16, 2015
RAF inhibitors that evade paradoxical MAPK pathway activationChao Zhang, Wayne Spevak, Ying Zhang, et al.
JAMA Oncology|July 8, 2021
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical TrialAndrew J Wagner, Paul L Severson, Anthony F Shields, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Nature Biotechnology|November 10, 2011
Interrogating the kinomeChao Zhang, Gaston Habets, Gideon Bollag
Pain|May 21, 2015
Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancerMichelle L Thompson, Juan M Jimenez-Andrade, Stephane Chartier, et al.
Cancer Cell|December 21, 2004
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivityClodagh C O'Shea, Leisa Johnson, Bridget Bagus, et al.
Clinical and Experimental Medicine|December 8, 2018
PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumorsYemarshet K Gebreyohannes, Elizabeth A Burton, Agnieszka Wozniak, et al.
Nature Communications|August 23, 2019
Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease modelElizabeth Spangenberg, Paul L Severson, Lindsay A Hohsfield, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2013
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitorChao Zhang, Prabha N Ibrahim, Jiazhong Zhang, et al.
Cancer Discovery|April 8, 2015
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397Catherine C Smith, Chao Zhang, Kimberly C Lin, et al.
JCI Insight|July 27, 2018
The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanomaOrsi Giricz, Yongkai Mo, Kimberly B Dahlman, et al.
Nature|October 16, 2015
RAF inhibitors that evade paradoxical MAPK pathway activationChao Zhang, Wayne Spevak, Ying Zhang, et al.
JAMA Oncology|July 8, 2021
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical TrialAndrew J Wagner, Paul L Severson, Anthony F Shields, et al.
Pageof 2